Structure · schematic
Peptide chain · Amylin-Analog
Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid.
Research areas*
* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.
Mechanism of action
- Cagrilintide is a long-acting analog of the hormone amylin, which is co-secreted with insulin by the beta cells of the pancreas.
- It acts at amylin and calcitonin receptors and influences satiety, gastric emptying and food intake.
- Cagrilintide is investigated primarily in combination with the GLP-1 analog semaglutide (the "CagriSema" combination) to achieve additive effects on body weight.
Research status
- Cagrilintide is in clinical development (Novo Nordisk).
- A Phase 1b study (2021) investigated co-administration of cagrilintide with semaglutide and observed enhanced weight reduction versus semaglutide alone.
- A 2025 study of the combination (CagriSema) in overweight and obesity confirmed substantial effects.
- Phase III studies (the REDEFINE programme) are ongoing; there is no standalone approval of cagrilintide to date.
Evidence level
Cited studies
- 2021Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- 2025Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Known risks
- 01Safety profile not conclusively established — no completed Phase III data
- 02Gastrointestinal side effects (nausea, vomiting) frequently described
- 03Injection-site reactions possible
- 04Interactions and long-term effects not fully characterised
- 05No long-term safety data available
Frequently asked questions
What is Cagrilintid?
Cagrilintide is a long-acting analog of the hormone amylin, which is co-secreted with insulin by the beta cells of the pancreas.
What type of peptide is Cagrilintid?
Cagrilintid belongs to the Amylin analog class.
Is Cagrilintid legal in Germany?
Cagrilintid is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Where can I buy Cagrilintid?
Peptica sells nothing and names no sources. Cagrilintid is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
Is Cagrilintid banned in sport (WADA)?
Cagrilintid is currently not on the WADA Prohibited List.
What are the known risks of Cagrilintid?
Documented risks include: Safety profile not conclusively established — no completed Phase III data; Gastrointestinal side effects (nausea, vomiting) frequently described. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is Cagrilintid?
The evidence is classified as “early clinical studies”. 2 studies are cited on this page.
What is the molecular weight of Cagrilintid?
Cagrilintid has a molar mass of about 4409 Da, with a plasma half-life of ~7–8 days (once weekly).
Which peptides are related to Cagrilintid?
Closely related entries: Semaglutid, Tirzepatid, Retatrutid. A direct side-by-side comparison is available via the compare function.
Related entries
Legal status
Germany
not approvedAustria
not approvedSwitzerland
not approvedEU
not approvedUSA
not approvedCanada
not approvedLegal status varies by country and can change. This is not legal advice.
Sources & methodology
- 2 peer-reviewed studies cited, linked to PubMed where available.
- Molecular data verified against PubChem and primary literature. PubChem CID 171397054
- Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.
Last editorially reviewed: 30 May 2026
Legal assessment
Cagrilintide does not yet have market approval and is investigated mainly in combination with semaglutide in Phase III studies. Obtaining it as a research chemical outside clinical studies is illegal and carries considerable safety risks.
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.
Anzeige
Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.